Atossa Therapeutics initiated with a Buy at H.C. Wainwright

H.C. Wainwright analyst Emily Bodnar initiated coverage of Atossa Therapeutics with a Buy rating and $4 price target. Atossa’s pipeline centers around Z-endoxifen, which is the active metabolite of tamoxifen, a drug initially approved in 1977 to treat advanced breast cancer, the analyst tells investors in a research note. With the company’s share price trading near cash levels, the firm believes investors are currently attributing no value to the pipeline, and sees significant upside potential on second half of 2024 catalysts.